title: Integrating Estimates of the Social and Individual Costs of Caregiving into Dementia Treatment Trials.
abstract: A variety of new treatments for dementia are awaiting or undergoing randomized clinical trails. These trials focus on outcomes such as changes in cognitive function, physical function, or amyloid plaques. What is quite important and is too often missing from these trials are estimates of the impact of these treatments on the social and individual costs of providing care for those facing dementia. Until outcomes such as family caregiver time and caregiver burden are included in trails of dementia treatments, the picture of how well these treatments work will be distressingly incomplete.
authors.affiliation: Editor in Chief, Health Services Insights, Texas A&M University Health Science Center, College Station, TX, USA.; Emeritus Regents Professor, School of Public Health, Texas A&M University Health Science Center, College Station, TX, USA.
authors.forename: Charles D
authors.initials: CD
authors.lastname: Phillips
keywords: Alzheimer’s; Biogen; Eli LIlly; caregiving; clinical trials; dementia; family caregivers; informal care